Drug Profile
VVZ 368
Alternative Names: VVZ-368Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Vivozon
- Class Analgesics
- Mechanism of Action Glycine plasma membrane transport protein inhibitors; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Pain in USA (PO)
- 28 Apr 2017 Early research in Pain in USA (PO) (Vivozon pipeline, April 2017)
- 28 Apr 2017 Vivozon has patent protection for benzamide derivatives for the treatment of pain in Korea, USA and China